{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:20:57Z","timestamp":1787005257736,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the onset of the COVID-19 pandemic, there have been concerns over the mental health impact of COVID-19. This is a review of the utilization of antidepressants, anxiolytics, and hypnotics since the COVID-19 pandemic was declared on March the 11th 2020. A number of reports so far have been based on large prescription databases for administrative use at the national or regional level, but mainly in high-income countries. We found studies reporting increased prescription rates of antidepressants, anxiolytics, and hypnotics during March 2020, which has been interpreted as hoarding of such medications. In the following months, most studies of antidepressant prescription rates did not display a clear pattern of change compared with prepandemic trends. In later phases of the pandemic small increases in utilization of antidepressants, with higher than predicted prescription rates, have been the most consistent finding, especially in youth. In most high-income countries, there were increasing trends in utilization of antidepressants also before 2020, which needs to be considered when estimating utilization during the pandemic, whereas for anxiolytics and hypnotics, the prepandemic patterns of prescriptions were more varying. Overall, after March 2020 we could not find any distinct changes in the utilization of anxiolytics and hypnotics during the COVID-19 pandemic. Most studies did not contain information about the prevalence of indicated psychiatric disorders in the studied populations. More studies are needed about the long-term effects of COVID-19, particularly regarding utilization of antidepressants. Research relating antidepressant utilization with the prevalence of major depression and anxiety disorders would promote a better understanding of how well antidepressant prescription rates reflect the needs of the population.<\/jats:p>","DOI":"10.1038\/s41398-024-02894-z","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:02:20Z","timestamp":1712239340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8495-8125","authenticated-orcid":false,"given":"Mikael","family":"Tiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0309-1345","authenticated-orcid":false,"given":"Giulio","family":"Castelpietra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Wesselhoeft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4298-3936","authenticated-orcid":false,"given":"Johan","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1372-4262","authenticated-orcid":false,"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"publisher","first-page":"368504211019854","DOI":"10.1177\/00368504211019854","volume":"104","author":"H Onyeaka","year":"2021","unstructured":"Onyeaka H, Anumudu CK, Al-Sharify ZT, Egele-Godswill E, Mbaegbu P. COVID-19 pandemic: a review of the global lockdown and its far-reaching effects. Sci Prog. 2021;104:368504211019854.","journal-title":"Sci Prog"},{"key":"2894_CR2","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF. The first eight months of Sweden\u2019s COVID-19 strategy and the key actions and actors that were involved. Acta Paediatr. 2020;12:2459\u201371.","DOI":"10.1111\/apa.15582"},{"key":"2894_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2215-0366(20)30168-1","volume":"7","author":"EA Holmes","year":"2020","unstructured":"Holmes EA, O\u2019Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7:547\u201360.","journal-title":"Lancet Psychiatry"},{"key":"2894_CR4","doi-asserted-by":"crossref","unstructured":"Kauhanen L, Wan Mohd Yunus WMA, Lempinen L, Peltonen K, Gyllenberg D, Mishina K, et al. A systematic review of the mental health changes of children and young people before and during the COVID-19 pandemic. Eur Child Adolesc Psychiatry. 2022;32:1\u201319.","DOI":"10.1007\/s00787-022-02060-0"},{"key":"2894_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/10870547231158750","volume":"27","author":"MA Rogers","year":"2023","unstructured":"Rogers MA, MacLean J. ADHD symptoms increased during the Covid-19 pandemic: a meta-analysis. J Atten Disord. 2023;27:800\u201311.","journal-title":"J Atten Disord"},{"key":"2894_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/nyas.14947","volume":"1520","author":"J Deng","year":"2023","unstructured":"Deng J, Zhou F, Hou W, Heybati K, Lohit S, Abbas U, et al. Prevalence of mental health symptoms in children and adolescents during the COVID-19 pandemic: a meta-analysis. Ann N Y Acad Sci. 2023;1520:53\u201373.","journal-title":"Ann N Y Acad Sci"},{"key":"2894_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jad.2021.06.021","volume":"293","author":"L Ma","year":"2021","unstructured":"Ma L, Mazidi M, Li K, Li Y, Chen S, Kirwan R, et al. Prevalence of mental health problems among children and adolescents during the COVID-19 pandemic: a systematic review and meta-analysis. J Affect Disord. 2021;293:78\u201389.","journal-title":"J Affect Disord"},{"key":"2894_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pedhc.2022.10.001","volume":"37","author":"R Kronk","year":"2023","unstructured":"Kronk R, Kim I, Nolfi D. Sleep in children with neurodevelopmental disabilities during COVID-19: an integrative review. J Pediatr Health Care. 2023;37:153\u201366.","journal-title":"J Pediatr Health Care"},{"key":"2894_CR9","doi-asserted-by":"crossref","unstructured":"Bilu Y, Flaks-Manov N, Bivas-Benita M, Akiva P, Kalkstein N, Yehezkelli Y, et al. Data-driven assessment of adolescents\u2019 mental health during the COVID-19 pandemic. J Am Acad Child Adolesc Psychiatry. 2023;62:920\u201337.","DOI":"10.1016\/j.jaac.2022.12.026"},{"key":"2894_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1001\/jamapsychiatry.2022.4165","volume":"80","author":"M Bliddal","year":"2023","unstructured":"Bliddal M, Rasmussen L, Andersen JH, Jensen PB, Pottegard A, Munk-Olsen T, et al. Psychotropic medication use and psychiatric disorders during the COVID-19 pandemic among danish children, adolescents, and young adults. JAMA Psychiatry. 2023;80:176\u201380.","journal-title":"JAMA Psychiatry"},{"key":"2894_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jad.2022.09.003","volume":"318","author":"FM Delpino","year":"2022","unstructured":"Delpino FM, da Silva CN, Jer\u00f4nimo JS, Mulling ES, da Cunha LL, Weymar MK, et al. Prevalence of anxiety during the COVID-19 pandemic: a systematic review and meta-analysis of over 2 million people. J Affect Disord. 2022;318:272\u201382.","journal-title":"J Affect Disord"},{"key":"2894_CR12","doi-asserted-by":"publisher","first-page":"e06677","DOI":"10.1016\/j.heliyon.2021.e06677","volume":"7","author":"MM Hossain","year":"2021","unstructured":"Hossain MM, Rahman M, Trisha NF, Tasnim S, Nuzhath T, Hasan NT, et al. Prevalence of anxiety and depression in South Asia during COVID-19: A systematic review and meta-analysis. Heliyon. 2021;7:e06677.","journal-title":"Heliyon"},{"key":"2894_CR13","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators.","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet 2021;398:1700\u201312.","journal-title":"Lancet"},{"key":"2894_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.sleep.2022.06.020","volume":"100","author":"MM AlRasheed","year":"2022","unstructured":"AlRasheed MM, Fekih-Romdhane F, Jahrami H, Pires GN, Saif Z, Alenezi AF, et al. The prevalence and severity of insomnia symptoms during COVID-19: a global systematic review and individual participant data meta-analysis. Sleep Med. 2022;100:7\u201323.","journal-title":"Sleep Med"},{"key":"2894_CR15","doi-asserted-by":"publisher","first-page":"e0253944","DOI":"10.1371\/journal.pone.0253944","volume":"16","author":"P Karlsson","year":"2021","unstructured":"Karlsson P, Nakitanda AO, Lofling L, Cesta CE. Patterns of prescription dispensation and over-the-counter medication sales in Sweden during the COVID-19 pandemic. PLoS ONE. 2021;16:e0253944.","journal-title":"PLoS ONE"},{"key":"2894_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07405-3","volume":"22","author":"AO Nakitanda","year":"2022","unstructured":"Nakitanda AO, Karlsson P, Lofling L, Cesta CE, Odsbu I. Antimicrobial use in Sweden during the COVID-19 pandemic: prescription fill and inpatient care requisition patterns. BMC Infect Dis. 2022;22:492.","journal-title":"BMC Infect Dis"},{"key":"2894_CR17","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/pds.5509","volume":"31","author":"I Selke Krulichova","year":"2022","unstructured":"Selke Krulichova I, Selke GW, Bennie M, Hajiebrahimi M, Nyberg F, Furst J, et al. Comparison of drug prescribing before and during the COVID-19 pandemic: a cross-national European study. Pharmacoepidemiol Drug Saf. 2022;31:1046\u201355.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2894_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.japh.2021.12.014","volume":"62","author":"KJ Suda","year":"2022","unstructured":"Suda KJ, Kim KC, Hernandez I, Gellad WF, Rothenberger S, Campbell A, et al. The global impact of COVID-19 on drug purchases: a cross-sectional time series analysis. J Am Pharm Assoc (2003). 2022;62:766\u201374.e6.","journal-title":"J Am Pharm Assoc (2003)"},{"key":"2894_CR19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/00912174221084818","volume":"58","author":"LT Ying","year":"2023","unstructured":"Ying LT, Yarema MC, Bousman CA. Dispensing patterns of mental health medications before and during the COVID-19 pandemic in Alberta, Canada: An interrupted time series analysis. Int J Psychiatry Med. 2023;58:172\u201384.","journal-title":"Int J Psychiatry Med"},{"key":"2894_CR20","doi-asserted-by":"publisher","first-page":"109654","DOI":"10.1016\/j.drugalcdep.2022.109654","volume":"241","author":"L King","year":"2022","unstructured":"King L, Hayashi K, Genberg B, Choi J, DeBeck K, Kirk G, et al. Prevalence and correlates of stocking up on drugs during the COVID-19 pandemic: data from the C3PNO Consortium. Drug Alcohol Depend. 2022;241:109654.","journal-title":"Drug Alcohol Depend"},{"key":"2894_CR21","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1192\/bjp.2022.112","volume":"221","author":"A Maguire","year":"2022","unstructured":"Maguire A, Kent L, O\u2019Neill S, O\u2019Hagan D, O\u2019Reilly D. Impact of the COVID-19 pandemic on psychotropic medication uptake: time-series analysis of a population-wide cohort. Br J Psychiatry. 2022;221:748\u201357.","journal-title":"Br J Psychiatry"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1192\/j.eurpsy.2022.2328","volume":"65","author":"D Winkler","year":"2022","unstructured":"Winkler D, Reichardt B, Rothenberg M, Rujescu D, Pjrek E. Prescriptions of psychopharmacologic drugs in Austria in 2019 and 2020\u2014implications of the COVID-19 pandemic. Eur Psychiatry. 2022;65:73.","journal-title":"Eur Psychiatry"},{"key":"2894_CR23","doi-asserted-by":"publisher","first-page":"e068993","DOI":"10.1136\/bmj-2021-068993","volume":"376","author":"Y Xie","year":"2022","unstructured":"Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. Br Med J. 2022;376:e068993.","journal-title":"Br Med J"},{"key":"2894_CR24","doi-asserted-by":"publisher","first-page":"e2124092","DOI":"10.1001\/jamanetworkopen.2021.24092","volume":"4","author":"M Hawrilenko","year":"2021","unstructured":"Hawrilenko M, Kroshus E, Tandon P, Christakis D. The association between school closures and child mental health during COVID-19. JAMA Netw Open. 2021;4:e2124092.","journal-title":"JAMA Netw Open"},{"key":"2894_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02315-7","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Ge F, Wang J, Yang H, Han X, Ying Z, et al. Trends in incident diagnoses and drug prescriptions for anxiety and depression during the COVID-19 pandemic: an 18-month follow-up study based on the UK Biobank. Transl Psychiatry. 2023;13:12.","journal-title":"Transl Psychiatry"},{"key":"2894_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jad.2022.11.068","volume":"323","author":"M Tiger","year":"2023","unstructured":"Tiger M, Wesselhoeft R, Karlsson P, Handal M, Bliddal M, Cesta CE, et al. Utilization of antidepressants, anxiolytics, and hypnotics during the COVID-19 pandemic in Scandinavia. J Affect Disord. 2023;323:292\u20138.","journal-title":"J Affect Disord"},{"key":"2894_CR27","unstructured":"OECD Stat, Pharmaceutical market (2021)."},{"key":"2894_CR28","doi-asserted-by":"publisher","first-page":"e226269","DOI":"10.1001\/jamanetworkopen.2022.6269","volume":"5","author":"TC Lee","year":"2022","unstructured":"Lee TC, Vigod S, Bortolussi-Courval E, Hanula R, Boulware DR, Lenze EJ, et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e226269.","journal-title":"JAMA Netw Open"},{"key":"2894_CR29","doi-asserted-by":"crossref","unstructured":"Wood SJ, Ilomaki J, Gould J, Tan GS, Raven M, Jureidini JN, et al. Dispensing of psychotropic medications to Australian children and adolescents before and during the COVID-19 pandemic, 2013-2021: a retrospective cohort study. Med J Aust. 2023;219:18\u201325.","DOI":"10.5694\/mja2.51948"},{"key":"2894_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/00048674221079740","volume":"57","author":"J de Oliveira Costa","year":"2023","unstructured":"de Oliveira Costa J, Gillies MB, Schaffer AL, Peiris D, Zoega H, Pearson SA. Changes in antidepressant use in Australia: a nationwide analysis (2015-2021). Aust N Z J Psychiatry. 2023;57:49\u201357.","journal-title":"Aust N Z J Psychiatry"},{"key":"2894_CR31","doi-asserted-by":"publisher","first-page":"1020023","DOI":"10.3389\/fpsyt.2022.1020023","volume":"13","author":"P Benistand","year":"2022","unstructured":"Benistand P, Vorilhon P, Laporte C, Bouillon-Minois JB, Brousse G, Bagheri R, et al. Effect of the COVID-19 pandemic on the psychotropic drug consumption. Front Psychiatry. 2022;13:1020023.","journal-title":"Front Psychiatry"},{"key":"2894_CR32","doi-asserted-by":"crossref","unstructured":"Frangou S, Travis-Lumer Y, Kodesh A, Goldberg Y, New F, Reichenberg A, et al. Increased incident rates of antidepressant use during the COVID-19 pandemic: interrupted time-series analysis of a nationally representative sample. Psychol Med. 2022;53:1\u20139.","DOI":"10.1017\/S0033291722001891"},{"key":"2894_CR33","doi-asserted-by":"publisher","first-page":"114704","DOI":"10.1016\/j.psychres.2022.114704","volume":"315","author":"L Pazzagli","year":"2022","unstructured":"Pazzagli L, Reutfors J, Lucian E, Zerial G, Perulli A, Castelpietra G. Increased antidepressant use during the COVID-19 pandemic: Findings from the Friuli Venezia Giulia region, Italy, 2015-2020. Psychiatry Res. 2022;315:114704.","journal-title":"Psychiatry Res"},{"key":"2894_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15360-0","volume":"23","author":"MLN Garcia","year":"2023","unstructured":"Garcia MLN, Martinez PF, Breton EF, Martinez Alfonso MM, Gil PS. Psychotropic consumption before and during COVID-19 in Asturias, Spain. BMC Public Health. 2023;23:494.","journal-title":"BMC Public Health"},{"key":"2894_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-023-00584-0","volume":"17","author":"I Kuitunen","year":"2023","unstructured":"Kuitunen I, Uimonen MM, Ponkilainen VT, Mattila VM. Primary care visits due to mental health problems and use of psychotropic medication during the COVID-19 pandemic in Finnish adolescents and young adults. Child Adolesc Psychiatry Ment Health. 2023;17:35.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"2894_CR36","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1089\/cap.2022.0037","volume":"32","author":"A Amill-Rosario","year":"2022","unstructured":"Amill-Rosario A, Lee H, Zhang C, dosReis S. Psychotropic prescriptions during the COVID-19 pandemic among U.S. children and adolescents receiving mental health services. J Child Adolesc Psychopharmacol. 2022;32:408\u201314.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"2894_CR37","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.3390\/ijerph19084782","volume":"19","author":"MDC Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez MDC, Diaz-Calvo V, Ruiz-Gonzalez C, Nievas-Soriano BJ, Rebollo-Lavado B, Parron-Carreno T. Consumption of psychiatric drugs in primary care during the COVID-19 Pandemic. Int J Environ Res Public Health. 2022;19:4782.","journal-title":"Int J Environ Res Public Health"},{"key":"2894_CR38","doi-asserted-by":"publisher","first-page":"154656","DOI":"10.1016\/j.scitotenv.2022.154656","volume":"829","author":"N Diaz-Camal","year":"2022","unstructured":"Diaz-Camal N, Cardoso-Vera JD, Islas-Flores H, Gomez-Olivan LM, Mejia-Garcia A. Consumption and ocurrence of antidepressants (SSRIs) in pre- and post-COVID-19 pandemic, their environmental impact and innovative removal methods: a review. Sci Total Environ. 2022;829:154656.","journal-title":"Sci Total Environ"},{"key":"2894_CR39","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/S2215-0366(20)30530-7","volume":"8","author":"R Armitage","year":"2021","unstructured":"Armitage R. Antidepressants, primary care, and adult mental health services in England during COVID-19. Lancet Psychiatry. 2021;8:e3.","journal-title":"Lancet Psychiatry"},{"key":"2894_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22085-4","volume":"12","author":"F Marazzi","year":"2022","unstructured":"Marazzi F, Piano Mortari A, Belotti F, Carra G, Cattuto C, Kopinska J, et al. Psychotropic drug purchases during the COVID-19 pandemic in Italy and their relationship with mobility restrictions. Sci Rep. 2022;12:19336.","journal-title":"Sci Rep"},{"key":"2894_CR41","doi-asserted-by":"publisher","first-page":"e2316642","DOI":"10.1001\/jamanetworkopen.2023.16642","volume":"6","author":"G Goyal","year":"2023","unstructured":"Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, et al. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023;6:e2316642.","journal-title":"JAMA Netw Open"},{"key":"2894_CR42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jad.2022.02.004","volume":"303","author":"E Stephenson","year":"2022","unstructured":"Stephenson E, O\u2019Neill B, Kalia S, Ji C, Crampton N, Butt DA, et al. Effects of COVID-19 pandemic on anxiety and depression in primary care: A retrospective cohort study. J Affect Disord. 2022;303:216\u201322.","journal-title":"J Affect Disord"},{"key":"2894_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jpm12020178","volume":"12","author":"IC Antonazzo","year":"2022","unstructured":"Antonazzo IC, Fornari C, Maumus-Robert S, Cei E, Paoletti O, Ferrara P, et al. Antidepressants drug use during COVID-19 waves in the Tuscan general population: an interrupted time-series analysis. J Pers Med. 2022;12:178.","journal-title":"J Pers Med"},{"key":"2894_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40520-022-02303-9","volume":"35","author":"A Marengoni","year":"2023","unstructured":"Marengoni A, Cangini A, Pierantozzi A, Onder G, Da Cas R, Ippoliti I, et al. Impact of COVID-19 pandemic on medication use in the older Italian population. Aging Clin Exp Res. 2023;35:443\u201353.","journal-title":"Aging Clin Exp Res"},{"key":"2894_CR45","doi-asserted-by":"publisher","first-page":"861643","DOI":"10.3389\/fpsyg.2022.861643","volume":"13","author":"A Lear-Claveras","year":"2022","unstructured":"Lear-Claveras A, Claveria A, Couso-Viana S, Nabbe P, Olivan-Blazquez B. Analysis of drug and health resource use before and after COVID-19 lockdown in a population undergoing treatment for depression or anxiety. Front Psychol. 2022;13:861643.","journal-title":"Front Psychol"},{"key":"2894_CR46","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3390\/ijerph19042135","volume":"19","author":"D Krupa","year":"2022","unstructured":"Krupa D, Czech M, Pinkas J, Mosiolek A. Impact of COVID-19 pandemic on the use of antidepressant and antianxiety pharmaceuticals as well as sick leave in Poland. Int J Environ Res Public Health. 2022;19:2135.","journal-title":"Int J Environ Res Public Health"},{"key":"2894_CR47","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1192\/bjp.bp.114.156786","volume":"207","author":"D Lewer","year":"2015","unstructured":"Lewer D, O\u2019Reilly C, Mojtabai R, Evans-Lacko S. Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Br J Psychiatry. 2015;207:221\u20136.","journal-title":"Br J Psychiatry"},{"key":"2894_CR48","doi-asserted-by":"publisher","first-page":"1028233","DOI":"10.3389\/fphar.2022.1028233","volume":"13","author":"PAE Saavedra","year":"2022","unstructured":"Saavedra PAE, Galato D, Silva CMD, da Silva ICR, da Silva EV. Dispensing of psychotropic drugs in the Brazilian capital city before and during the COVID-19 pandemic (2018-2020). Front Pharmacol. 2022;13:1028233.","journal-title":"Front Pharmacol"},{"key":"2894_CR49","doi-asserted-by":"publisher","first-page":"109176","DOI":"10.1016\/j.drugalcdep.2021.109176","volume":"229","author":"C de Dios","year":"2021","unstructured":"de Dios C, Fernandes BS, Whalen K, Bandewar S, Suchting R, Weaver MF, et al. Prescription fill patterns for benzodiazepine and opioid drugs during the COVID-19 pandemic in the United States. Drug Alcohol Depend. 2021;229:109176.","journal-title":"Drug Alcohol Depend"},{"key":"2894_CR50","doi-asserted-by":"crossref","unstructured":"Diaz MS, Martin-Calvo ML, Mateos-Campos R. Trends in the use of anxiolytics in castile and Leon, Spain, between 2015-2020: evaluating the impact of COVID-19. Int J Env Res Public Health. 2021;18:1\u201310.","DOI":"10.3390\/ijerph18115944"},{"key":"2894_CR51","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1017\/S0033291721004839","volume":"53","author":"M Levaillant","year":"2023","unstructured":"Levaillant M, Wathelet M, Lamer A, Riquin E, Gohier B, Hamel-Broza JF. Impact of COVID-19 pandemic and lockdowns on the consumption of anxiolytics, hypnotics and antidepressants according to age groups: a French nationwide study. Psychol Med. 2023;53:2861\u20137.","journal-title":"Psychol Med"},{"key":"2894_CR52","doi-asserted-by":"publisher","first-page":"102552","DOI":"10.1016\/j.aprim.2022.102552","volume":"55","author":"S Garc\u00eda Diez","year":"2023","unstructured":"Garc\u00eda Diez S, De Nicol\u00e1s Vald\u00e9s M, Di\u00e9guez Varela C, Fern\u00e1ndez Mart\u00ednez P, Su\u00e1rez Gil P, Navarro Rodr\u00edguez Y. Impact of COVID-19 lockdown on the prescription of benzodiazepines. Aten Primaria. 2023;55:102552.","journal-title":"Aten Primaria"},{"key":"2894_CR53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/jech-2021-216732","volume":"76","author":"M Estrela","year":"2022","unstructured":"Estrela M, Silva TM, Gomes ER, Pineiro M, Figueiras A, Roque F, et al. Prescription of anxiolytics, sedatives, hypnotics and antidepressants in outpatient, universal care during the COVID-19 pandemic in Portugal: a nationwide, interrupted time-series approach. J Epidemiol Community Health. 2022;76:335\u201340.","journal-title":"J Epidemiol Community Health"},{"key":"2894_CR54","doi-asserted-by":"publisher","first-page":"1131357","DOI":"10.3389\/fphar.2023.1131357","volume":"14","author":"FS Del Fiol","year":"2023","unstructured":"Del Fiol FS, Bergamaschi CC, Lopes LC, Silva MT, Barberato-Filho S. Sales trends of psychotropic drugs in the COVID-19 pandemic: a national database study in Brazil. Front Pharm. 2023;14:1131357.","journal-title":"Front Pharm"},{"key":"2894_CR55","doi-asserted-by":"publisher","first-page":"e2131012","DOI":"10.1001\/jamanetworkopen.2021.31012","volume":"4","author":"SA Milani","year":"2021","unstructured":"Milani SA, Raji MA, Chen L, Kuo YF. Trends in the use of benzodiazepines, Z-hypnotics, and serotonergic drugs among US women and men before anD during the COVID-19 pandemic. JAMA Netw Open. 2021;4:e2131012.","journal-title":"JAMA Netw Open"},{"key":"2894_CR56","doi-asserted-by":"crossref","unstructured":"Ferreira DA, da Silva PIF, de Azevedo MRF, de Sousae JRR, de Azevedo RLW. Prescription and dispensing of benzodiazepines in times of the Covid-19 pandemic in Brazil. Rev Pesqui. 2022;14:1\u20138.","DOI":"10.9789\/2175-5361.rpcfo.v14.11460"},{"key":"2894_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/da.23228","volume":"39","author":"S Uthayakumar","year":"2022","unstructured":"Uthayakumar S, Tadrous M, Vigod SN, Kitchen SA, Gomes T. The effects of COVID-19 on the dispensing rates of antidepressants and benzodiazepines in Canada. Depression Anxiety. 2022;39:156\u201362.","journal-title":"Depression Anxiety"},{"key":"2894_CR58","doi-asserted-by":"publisher","first-page":"731297","DOI":"10.3389\/fpsyt.2021.731297","volume":"12","author":"M Wolfschlag","year":"2021","unstructured":"Wolfschlag M, Grudet C, Hakansson A. Impact of the COVID-19 Pandemic on the General Mental Health in Sweden: no observed changes in the dispensed amount of common psychotropic medications in the region of Scania. Front Psychiatry. 2021;12:731297.","journal-title":"Front Psychiatry"},{"key":"2894_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.puhe.2021.10.005","volume":"201","author":"B Farina","year":"2021","unstructured":"Farina B, Massullo C, De Rossi E, Carbone GA, Serraino R, Imperatori C. Psychotropic medications sales during COVID-19 outbreak in Italy changed according to the pandemic phases and related lockdowns. Public Health. 2021;201:75\u20137.","journal-title":"Public Health"},{"key":"2894_CR60","doi-asserted-by":"crossref","unstructured":"Chua KP, Volerman A, Conti RM. Prescription drug dispensing to US children during the COVID-19 pandemic. Pediatrics. 2021;148:1\u201312.","DOI":"10.1542\/peds.2021-049972"},{"key":"2894_CR61","doi-asserted-by":"publisher","first-page":"e27664","DOI":"10.1097\/MD.0000000000027664","volume":"100","author":"ME Hirschtritt","year":"2021","unstructured":"Hirschtritt ME, Slama N, Sterling SA, Olfson M, Iturralde E. Psychotropic medication prescribing during the COVID-19 pandemic. Medicine. 2021;100:e27664.","journal-title":"Medicine"},{"key":"2894_CR62","doi-asserted-by":"publisher","first-page":"886652","DOI":"10.3389\/fphar.2022.886652","volume":"13","author":"C Leong","year":"2022","unstructured":"Leong C, Kowalec K, Eltonsy S, Bolton JM, Enns MW, Tan QR, et al. Psychotropic medication use before and during COVID-19: a population-wide study. Front Pharmacol. 2022;13:886652.","journal-title":"Front Pharmacol"},{"key":"2894_CR63","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1377\/hlthaff.2021.00028","volume":"40","author":"I Nason","year":"2021","unstructured":"Nason I, Stein DT, Frank RG, Stein MB. Decline in new starts of psychotropic medications during the COVID-19 pandemic. Health Aff. 2021;40:904\u20139.","journal-title":"Health Aff"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02894-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02894-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:02:38Z","timestamp":1712239358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-02894-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-02894-z","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"29 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JR reports participation in regulator-mandated research projects funded by pharmaceutical companies, all with funds paid to the institution where he is employed (no personal fees) and with no relation to the work reported in this paper. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}